Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4F29C)

• Drug Name: Crizotinib Drug Info
• Synonyms: Xalkori (TN); novel ALK inhibitors

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Approved	[1]

• Cross-matching ID:
  PubChem CID: 11626560
  ChEBI ID: CHEMBL601719
  CAS Number: CAS 877399-52-5
  TTD Drug ID: DM4F29C
  VARIDT Drug ID: DR00523
  INTEDE Drug ID: DR0387
  ACDINA Drug ID: D00154

Molecule-Related Drug Atlas

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[12]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[13]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[14]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[15]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[16]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[17]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[18]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[19]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[16]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[20]

Drug(s) Targeting ALK tyrosine kinase receptor (ALK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[21]
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[22]
Brigatinib	DM7W94S	Anaplastic large cell lymphoma	2A90.A	Approved	[23]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[17]
Ceritinib	DMB920Z	Non-small-cell lung cancer	2C25.Y	Approved	[24]
Alectinib	DMP1I6Y	Lung cancer	2C25.0	Approved	[25]
Ensartinib	DMIKDCQ	Non-small-cell lung cancer	2C25.Y	Phase 3	[17]
PF-06463922	DMKM7EW	Non-small-cell lung cancer	2C25.Y	Phase 2	[26]
AP26113	DMYBQEF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[27]
TSR-011	DMFOR9Y	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[28]

Drug(s) Targeting Proto-oncogene c-Ros (ROS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[21]
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[22]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[17]
AB-106	DMEW62S	Non-small-cell lung cancer	2C25	Phase 2	[29]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[30]
Carboxamide derivative 4	DMU5GKC	N. A.	N. A.	Patented	[31]
Imidazo[1,2-b]pyridazine derivative 2	DM1JYNW	Solid tumour/cancer	2A00-2F9Z	Patented	[32]
Imidazo[1,2-b]pyridazine derivative 3	DMPDTG0	Solid tumour/cancer	2A00-2F9Z	Patented	[32]
PMID28270010-Compound-Figure21-b	DM6IYAT	Brain metastases	2D50	Patented	[32]
Imidazo[1,2-b]pyridazine derivative 1	DMULTAI	Solid tumour/cancer	2A00-2F9Z	Patented	[32]

Drug(s) Targeting HGF/Met signaling pathway (HGF/Met pathway)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fosgonimeton	DMXMAJA	Alzheimer disease	8A20	Phase 2/3	[33]
SAIT301	DMLU6J0	Nasopharyngeal carcinoma	2B6B	Investigative	[34]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[35]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[36]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[37]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[38]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[37]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[37]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[39]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[37]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[40]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[41]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[42]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[43]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[44]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[4]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[45]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[46]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[47]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[48]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[45]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[49]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[50]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[51]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[4]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[52]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[46]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[48]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[53]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[48]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[54]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[55]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[57]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[58]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[59]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[60]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[61]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[55]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[62]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[63]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[64]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[65]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[66]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[67]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[68]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[69]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[70]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[71]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[66]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[72]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[73]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[74]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[75]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[76]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[77]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[78]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[79]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[77]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[74]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[80]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[81]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[81]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[81]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[83]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[81]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[82]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[81]

Drug(s) Affected By CD44 antigen (CD44)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[86]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Selenium	DM25CGV	N. A.	N. A.	Approved	[88]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[89]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[90]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[92]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[93]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[94]

Drug(s) Affected By Epithelial cell adhesion molecule (EPCAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[92]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[96]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[99]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[100]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[101]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[102]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[103]

Drug(s) Affected By Insulin-induced gene 1 protein (INSIG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[104]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[105]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[106]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[107]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[108]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[107]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[109]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[110]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[111]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[110]

Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[112]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[113]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[114]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[115]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[114]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[116]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[106]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]

Drug(s) Affected By Sterol regulatory element-binding protein 2 (SREBF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[117]
Selenium	DM25CGV	N. A.	N. A.	Approved	[118]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[119]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[116]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[120]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[121]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[122]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[123]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[124]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[123]

Drug(s) Affected By Acetyl-CoA carboxylase 1 (ACACA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[125]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[126]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[127]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[128]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[116]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[120]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[129]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[108]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[130]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[131]

Drug(s) Affected By Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[113]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[132]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[133]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[134]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[135]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[136]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[137]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[138]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[139]

Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[117]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[140]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[141]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[142]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[143]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[144]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[133]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[145]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[134]
Luvox	DMJKROX	Anxiety disorder	6B00-6B0Z	Approved	[146]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[147]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[148]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[149]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[150]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[151]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[152]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[153]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[154]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[155]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[156]

Drug(s) Affected By Bcl-2-like protein 11 (BCL2L11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[157]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[158]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[159]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[160]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[92]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[161]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[162]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[163]
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[164]

Drug(s) Affected By Follitropin subunit beta (FSHB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[165]
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[166]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[167]
Cetrorelix	DMFD9Q6	Ovarian stimulation	LB45.1	Approved	[168]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[169]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[170]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[171]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[172]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[101]
Naltrexone	DMUL45H	Alcohol dependence	6C40.2	Approved	[173]

Drug(s) Affected By Lutropin subunit beta (LHB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[174]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[175]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[176]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[177]
Alprazolam	DMC7XDN	Anxiety		Approved	[178]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Norethindrone acetate	DMDGCQP	N. A.	N. A.	Approved	[175]
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[177]
Cetrorelix	DMFD9Q6	Ovarian stimulation	LB45.1	Approved	[168]
Ganirelix	DMGMB30	Ovulation dysfunction	5A80	Approved	[179]

Drug(s) Affected By Tyrosine-protein kinase Lck (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[113]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[108]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[109]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[180]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[181]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[182]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[183]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[184]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[185]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[186]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[187]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[150]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[188]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[189]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[188]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[190]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[191]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[192]

Drug(s) Affected By Histone H2AX (H2AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[193]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[194]
Selenium	DM25CGV	N. A.	N. A.	Approved	[118]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[195]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[196]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[197]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[198]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[199]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[200]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[201]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[202]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[203]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[204]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[205]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[206]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[207]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[208]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[209]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[210]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[211]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[212]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[203]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[213]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[214]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[215]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[202]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[117]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[205]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[206]

Drug(s) Affected By Ras GTPase-activating-like protein IQGAP1 (IQGAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[216]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[144]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[217]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[218]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[219]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[167]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[99]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[220]

Drug(s) Affected By Small ribosomal subunit protein eS6 (RPS6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[221]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[132]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[222]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[223]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[224]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[225]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[227]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[217]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[218]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 2 (BIRC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[228]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[229]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[230]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[231]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[93]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[232]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[233]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[234]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[235]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[217]

Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[236]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[236]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[237]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[117]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[238]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[89]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[239]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[240]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[241]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[242]

Drug(s) Affected By Mast/stem cell growth factor receptor Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[243]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[244]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[113]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[120]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[92]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[245]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[247]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[248]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[249]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ALK tyrosine kinase receptor (ALK)	TTPMQSO	ALK_HUMAN	Modulator	[2]
HGF/Met signaling pathway (HGF/Met pathway)	TTKA5LP	NOUNIPROTAC	Inhibitor	[3]
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Modulator	[2]
Proto-oncogene c-Ros (ROS1)	TTSZ6Y3	ROS1_HUMAN	Modulator	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[4]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[4]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5) Main DME	DEIBDNY	CP3A5_HUMAN	Substrate	[6]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Post-Translational Modifications	[7]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[8]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Gene/Protein Processing	[9]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[9]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Gene/Protein Processing	[9]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[8]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Gene/Protein Processing	[10]
E3 ubiquitin-protein ligase XIAP	OT24GP9B	XIAP_HUMAN	Gene/Protein Processing	[9]
Epithelial cell adhesion molecule (EPCAM)	OTHBZK5X	EPCAM_HUMAN	Gene/Protein Processing	[10]
Follitropin subunit beta (FSHB)	OTGLS283	FSHB_HUMAN	Protein Interaction/Cellular Processes	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
• [4] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [5] Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
• [6] Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
• [7] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [8] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [9] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [10] Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
• [11] Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.
• [12] Clinical pipeline report, company report or official report of Exelixis (2011).
• [13] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [22] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [23] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
• [25] CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90.
• [26] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.
• [27] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [28] Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 2012 Oct;136(10):1201-4.
• [29] Clinical pipeline report, company report or official report of AnHeart Therapeutics.
• [30] National Cancer Institute Drug Dictionary (drug id 766123).
• [31] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [32] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [33] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis. 2022;86(3):1399-1413.
• [34] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [35] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [36] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [37] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [38] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [39] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [40] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [41] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [42] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [43] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [44] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [45] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [46] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [47] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [48] FDA Drug Development and Drug Interactions
• [49] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [50] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [51] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [52] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [53] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [54] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [55] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [56] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [57] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [58] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [59] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [60] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [61] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [62] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [63] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [64] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [65] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [66] Drug Interactions Flockhart Table
• [67] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [68] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [69] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [70] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [71] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [72] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [73] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [74] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [75] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [76] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [77] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [78] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [79] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [80] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [81] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [82] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [83] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [84] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [85] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [86] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [87] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [88] Promotion of the articular cartilage proteoglycan degradation by T-2 toxin and selenium protective effect. J Zhejiang Univ Sci B. 2008 Jan;9(1):22-33. doi: 10.1631/jzus.B071322.
• [89] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [90] Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
• [91] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [92] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [93] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [94] Thermochemotherapy effect of nanosized As2O3/Fe3O4 complex on experimental mouse tumors and its influence on the expression of CD44v6, VEGF-C and MMP-9. BMC Biotechnol. 2009 Oct 5;9:84. doi: 10.1186/1472-6750-9-84.
• [95] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [96] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [97] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [98] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [99] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [100] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [101] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [102] Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett. 2007 Feb 8;246(1-2):253-61. doi: 10.1016/j.canlet.2006.03.002. Epub 2006 Apr 18.
• [103] Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem. 2011 Oct;112(10):2850-64. doi: 10.1002/jcb.23199.
• [104] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [105] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [106] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [107] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [108] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [109] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [110] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [111] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [112] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [113] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [114] Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
• [115] Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
• [116] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [117] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [118] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [119] Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol. 2010 Apr 15;79(8):1200-9. doi: 10.1016/j.bcp.2009.12.007. Epub 2009 Dec 14.
• [120] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [121] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [122] Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr. 2005 Oct;135(10):2305-12. doi: 10.1093/jn/135.10.2305.
• [123] Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
• [124] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [125] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [126] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [127] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [128] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [129] Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
• [130] Comparative effects of fructose and glucose on lipogenic gene expression and intermediary metabolism in HepG2 liver cells. PLoS One. 2011;6(11):e26583. doi: 10.1371/journal.pone.0026583. Epub 2011 Nov 11.
• [131] Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. J Toxicol Sci. 2015 Feb;40(1):127-36. doi: 10.2131/jts.40.127.
• [132] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [133] Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
• [134] Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
• [135] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [136] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [137] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [138] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [139] CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009 Aug;2(4):362-70. doi: 10.1161/CIRCGENETICS.109.857839. Epub 2009 Jun 3.
• [140] Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
• [141] Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x.
• [142] Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
• [143] Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
• [144] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [145] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [146] Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine. Europace. 2010 Feb;12(2):282-3. doi: 10.1093/europace/eup332. Epub 2009 Oct 29.
• [147] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [148] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [149] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [150] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [151] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [152] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [153] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [154] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [155] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [156] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [157] Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther. 2007 Mar;6(3):1031-8. doi: 10.1158/1535-7163.MCT-06-0643. Epub 2007 Mar 5.
• [158] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [159] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [160] An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
• [161] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [162] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010 Feb;15(2):219-29. doi: 10.1007/s10495-009-0424-9.
• [163] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [164] BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014 Oct;13(10):2315-27. doi: 10.1158/1535-7163.MCT-14-0258. Epub 2014 Jul 22.
• [165] Suppression of spermatogenesis in patients with Beh?et's disease treated with cyclophosphamide and colchicine. Fertil Steril. 1981 Jul;36(1):76-80. doi: 10.1016/s0015-0282(16)45622-0.
• [166] [Kuntai capsule combined with gonadotropin releasing hormone agonist in treatment of moderate-severe endometriosis: a clinical observation]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Nov;34(11):1288-91.
• [167] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [168] Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Exp Clin Endocrinol Diabetes. 1999;107(1):63-9. doi: 10.1055/s-0029-1212075.
• [169] Aromatase inhibition, testosterone, and seizures. Epilepsy Behav. 2004 Apr;5(2):260-3. doi: 10.1016/j.yebeh.2003.12.001.
• [170] Male sexual dysfunction during treatment with cimetidine. Br Med J. 1979 Mar 10;1(6164):659. doi: 10.1136/bmj.1.6164.659.
• [171] Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009 Jan;34(1):129-39. doi: 10.1016/j.psyneuen.2008.08.015. Epub 2008 Oct 5.
• [172] Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab. 2000 May;85(5):1918-22. doi: 10.1210/jcem.85.5.6527.
• [173] Chronic naltrexone treatment induces desensitization of the luteinizing hormone pulse generator for opioid blockade in hyperprolactinemic patients. J Clin Endocrinol Metab. 1995 May;80(5):1739-42. doi: 10.1210/jcem.80.5.7745028.
• [174] Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol. 1999 Jan;6(1):19-23. doi: 10.1046/j.1442-2042.1999.06128.x.
• [175] Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat. Mol Cell Endocrinol. 2010 Oct 26;328(1-2):16-21. doi: 10.1016/j.mce.2010.06.010. Epub 2010 Jun 25.
• [176] Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
• [177] Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states. J Clin Endocrinol Metab. 1987 Mar;64(3):508-12. doi: 10.1210/jcem-64-3-508.
• [178] The effect of alprazolam on serum cortisol and luteinizing hormone pulsatility in normal women and in women with stress-related anovulation. J Clin Endocrinol Metab. 1995 Mar;80(3):818-23. doi: 10.1210/jcem.80.3.7883836.
• [179] Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online. 2011 Mar;22(3):263-71. doi: 10.1016/j.rbmo.2010.11.002. Epub 2010 Nov 13.
• [180] Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
• [181] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [182] Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
• [183] Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
• [184] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [185] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [186] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [187] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [188] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [189] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [190] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [191] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [192] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [193] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [194] Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
• [195] Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
• [196] Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
• [197] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [198] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [199] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [200] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [201] The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
• [202] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [203] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [204] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [205] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [206] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [207] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [208] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [209] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [210] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [211] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [212] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [213] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [214] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [215] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [216] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [217] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [218] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [219] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [220] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [221] Cannabidiol Reduces Leukemic Cell Size - But Is It Important?. Front Pharmacol. 2017 Mar 24;8:144. doi: 10.3389/fphar.2017.00144. eCollection 2017.
• [222] D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
• [223] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [224] Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY). 2012 Dec;4(12):952-65. doi: 10.18632/aging.100521.
• [225] Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901.
• [226] Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
• [227] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [228] Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
• [229] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [230] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [231] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [232] Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO). Int J Biochem Cell Biol. 2019 Nov;116:105615. doi: 10.1016/j.biocel.2019.105615. Epub 2019 Sep 17.
• [233] The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
• [234] Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol. 2005 Sep;75(3):212-20. doi: 10.1111/j.1600-0609.2005.00498.x.
• [235] Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther. 2002 Jul;1(9):667-77.
• [236] Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
• [237] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [238] ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
• [239] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [240] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [241] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [242] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
• [243] Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
• [244] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [245] [Demethylation effect of inhibitor As2O3 on expression of SHP-1 and C-kit genes in leukemia HL-60 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):613-6. doi: 10.7534/j.issn.1009-2137.2013.03.015.
• [246] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [247] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [248] Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010 Apr 12;207(4):731-50. doi: 10.1084/jem.20091488. Epub 2010 Apr 5.
• [249] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.